Premium
HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation
Author(s) -
Gripp Karen W.,
Lin Angela E.,
Stabley Deborah L.,
Nicholson Linda,
Scott Charles I.,
Doyle Daniel,
Aoki Yoko,
Matsubara Yoichi,
Zackai Elaine H.,
Lapunzina Pablo,
GonzalezMeneses Antonio,
Holbrook Jennifer,
Agresta Cynthia A.,
Gonzalez Iris L.,
SolChurch Katia
Publication year - 2005
Publication title -
american journal of medical genetics part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.064
H-Index - 112
eISSN - 1552-4833
pISSN - 1552-4825
DOI - 10.1002/ajmg.a.31047
Subject(s) - hras , costello syndrome , missense mutation , mutation , medicine , genotype , phenotype , genetics , biology , gene , kras
Costello syndrome is a rare condition comprising mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy, and/or atrial tachycardia), tumor predisposition, and skin and musculoskeletal abnormalities. Recently mutations in HRAS were identified in 12 Japanese and Italian patients with clinical information available on 7 of the Japanese patients. To expand the molecular delineation of Costello syndrome, we performed mutation analysis in 34 North American and 6 European (total 40) patients with Costello syndrome, and detected missense mutations in HRAS in 33 (82.5%) patients. All mutations affected either codon 12 or 13 of the protein product, with G12S occurring in 30 (90.9%) patients of the mutation‐positive cases. In two patients, we found a mutation resulting in an alanine substitution in position 12 (G12A), and in one patient, we detected a novel mutation (G13C). Five different HRAS mutations have now been reported in Costello syndrome, however genotype–phenotype correlation remains incomplete. © 2005 Wiley‐Liss, Inc.